Interferon Gamma Release Assays (IGRAs) are the leading diagnostic segment. They are increasingly preferred over traditional Tuberculin Skin Tests (TST) due to their superior specificity, faster turnaround times, and ability to minimize cross-reactivity with the BCG vaccination.
The market is characterized by several prominent diagnostic and life sciences companies, including QIAGEN, Oxford Immunotec, bioMérieux, Thermo Fisher Scientific, ARKRAY Inc., F. Hoffmann-La Roche Ltd., Abbott Laboratories, Creative Diagnostics, Bio-Techne Corporation, and Danaher Corporation.
Growth is primarily fueled by the WHO’s "End TB Strategy" targets, an increasing incidence of TB in high-burden countries, and the rising need for screening vulnerable populations, such as People Living with HIV (PLHIV) and close household contacts of active TB patients.
While North America currently leads in market share due to advanced infrastructure, the Asia-Pacific region is anticipated to be the fastest-growing market. This growth is driven by high disease prevalence, rapid urbanization, and increasing government investments in healthcare infrastructure in countries like India and China.
The primary challenges include the high cost of IGRA tests compared to traditional skin tests, a lack of necessary laboratory infrastructure in resource-constrained settings, and the clinical difficulty of distinguishing between latent infection and active TB disease.
Digital health integration is a major trend, with the incorporation of AI-powered data analytics, mobile health platforms for remote test reporting, and digital diagnostic platforms. These innovations are improving test interpretation and expanding diagnostic reach into rural and underserved areas.
PLHIV represent one of the most critical application segments. Because this population is at a high risk of latent TB progressing to active disease, global health agencies and NGOs have prioritized regular screening for this group, driving significant demand for sensitive diagnostic solutions.
Key developments include QIAGEN’s partnership with FIND to improve testing accessibility in Africa, bioMérieux’s USD 150 million investment in manufacturing facilities in France, and the US FDA granting breakthrough designation to Thermo Fisher Scientific’s novel digital TB test.
Diagnostic laboratories remain the dominant end-use segment. Their leadership is attributed to their centralized infrastructure, high testing capacity, and ability to manage complex assays and multi-disease workflows essential for national screening programs.
